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Abstract 
Introduction: Doxorubicin is the drug of choice in the treatment of many malignant neoplasms, but 
its use is limited due to the risk of developing severe cardiomyopathy. This problem necessitates the 
prevention, early diagnosis and treatment of cardiomyopathy. 
Material and Methods: The study was conducted on 80 male white Wistar rats, which were 
administered the following drugs during the experiment: doxorubicin (Teva) at a dose of 20 mg /kg, 
ethoxydol at a dose of 50 mg/kg, carbamylated darbepoetin at a dose of 50 mg/kg. The hearts of the 
rats were perfused in the installation of a Langendorf-isolated heart. All rats were recorded 
contractility indicators: maximum intraventricular pressure (IVP) (mm Hg), minimum IVP (mm Hg), 
average IVP (mm Hg), pulse IVP (mm. Hg), heart rate (HR, beats/min), maximum myocardial 
contraction rate (+ dP/dtmax, mm Hg/sec), maximum myocardial relaxation rate (-dP/dtmax, mm 
Hg/sec.), a test was performed with high-frequency stimulation. To assess the reserve capacity of 
the myocardium, we used the Tension-Time Index (tTTI) test of the “voltage over time” index. 
Results: When used as a cardioprotector of ethoxydol at a dose of 50 mg/kg, a decrease in the toxic 
effect of DR and an improvement in performance by 14.8% compared with the group of DR. The 
degree of change in contractility indicators compared with the positive control group was 48.7%. As 
a result of CDEPO at a dose of 50 mg/kg, there is also a positive trend in the change in myocardial 
contractility, but to a lesser extent than in ethoxydol. The difference in performance compared with 
the DR group is 8.6%. The greatest cardioprotective effect was achieved by the introduction of a 
combination of DR and CDEPO. The increase in contractility compared with the doxorubicin group 
was 23.9%. The severity of changes in contractility indicators decreased to 38.5% compared with the 
positive control group. This trend in the dynamics of myocardial contractility indices can be traced 
both in the conditions of perfusion with norcalcium and hypercalcium solutions. 
Conclusion: The most pronounced cardioprotective effect on the model of doxorubicin 
cardiomyopathy is determined by using a combination of carbamylated darbepoetin at a dose of 50 
mkg/kg with ethoxydol at a dose of 50 mg/kg. 
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INTRODUCTION 
The widespread demand for doxorubicin in medicine 
is due to the effectiveness and spectrum of its antitumor 
action. This cytostatic agent is the drug of choice for the 
treatment of most malignant tumors. However, the use 
of anthracycline drugs is limited due to the risk of 
developing severe cardiomyopathy, which is 
accompanied by progressive systolic dysfunction of the 
left ventricle (LV), leading to irreversible congestive 
heart failure (Danilenko 2018). This problem 
necessitates prevention, early diagnosis and treatment 
of cardiomyopathy. One of the current trends in the 
prevention of the occurrence of this side effect is the use 
of drugs with cardioprotective action. There are certain 
patterns in the interaction of drugs, manifested by 
potentiation, summation or additive effect, which greatly 
increases the chance of preventing the development of 
toxic side effects when using a combination of drugs with 
cardioprotective effects. 
The search for substances capable of affecting the 
pathogenetic cascades of apoptosis and cell necrosis is 
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one of the main tasks of modern pharmacology (Bogus 
et al. 2018, Denisyuk et al. 2016, Dzhimak et al. 2017, 
Gumanova et al. 2007, Kolesnichenko et al. 2018, 
Majorova et al. 2018, Peresypkina et al. 2019, Soldatov 
et al. 2018, Trauelsen et al. 2017). The main focus of 
research development is focused on oxidative stress 
(Dzhimak et al. 2017, Gumanova et al. 2007, 
Kolesnichenko et al. 2018, Peresypkina et al. 2019), 
inflammation (Denisuk et al. 2015, Denisyuk et al. 2016, 
Soldatov et al. 2018), nitrogen oxide imbalance 
(Korokina et al. 2018, Pokrovskii et al. 2017, Rajkumar 
et al. 2016) and intracellular secondary messengers 
(Gureev et al. 2014, Ragulina et al. 2017). Currently, one 
of the most effective drugs with tissue-protective 
properties is carbamylated darbepoetin, a modification 
of the glycoprotein hormone erythropoietin (EPO), also 
known as the hematopoietic hormone, but with a wide 
range of effects besides stimulating hematopoiesis 
(Gureev et al. 2014, Shabelnikova 2016, Shabelnikova 
et al. 2014, 2015) The ability to activate the 
phosphorylation of protein kinases, such as STAT-5, 
PI3K, Akt, Ras, the set of which varies according to the 
type of tissue (Kolesnichenko et al. 2018).  
Also today, the use of antioxidants as a 
cardioprotector is important. A special role among 
substances based on natural metabolites is given to 
fumaric acid preparations. One of the promising ways to 
correct the level of metabolic acidosis and prolongation 
of energy production is the use of Krebs cycle 
intermediates (Danilenko et al. 2016, Kukes and 
Goroshko 2013). More attention is focused on easily 
assimilable intermediates - succinate and malate. The 
use of succinate is based on the fact that its oxidation 
reaction to fumarate occurs due to FAD-dependent 
dehydrogenase (the flavin nature of succinate 
dehydrogenase) and is independent of the presence of 
oxidized forms of NADH. In turn, another intermediate, 
malate, occupies a key position in the malate 
oxaloacetate cycle. Malate is the only substrate of the 
Krebs cycle, capable of reducing cytochrome b5 in the 
presence of NADH in low concentrations. Penetrating 
into the mitochondria, malate drops electrons on the 
respiratory chain and turns into oxaloacetate (ASC), 
which is again transformed into malate. The special role 
of malate in the regulation of redox processes in the 
myocardium is mediated by its ability to increase the 
respiratory control coefficient of mitochondria, restore 
cytochrome b5 in the presence of NADH, as well as a 
high content of malate dehydrogenase compared to 
other dehydrogenases of Krebs cycle substrates, and it 
also has an inhibitory effect common to antioxidants free 
radical processes (Kolesnichenko et al. 2018). 
MATERIALS AND METHODS 
The study was conducted on 80 male Wistar white 
rats. The study was conducted according to the method 
“Method for assessing the cardioprotective activity of 
pharmacological agents” (Danilenko et al. 2018). All rats 
were randomly divided into 5 groups. The first group - 
intact animals (positive control), intragastrically 
administered 0.9% NaCl. The second group, the control 
(negative control), doxorubicin (Teva) was administered 
intragastrically to the animals in a cumulative dose of 20 
mg/kg once. The third group consisted of animals, 
which, against the background of a single intragastric 
administration of doxorubicin, were administered 
ethoxydol at a dose of 50 mg/kg. The fourth group 
includes animals injected with doxorubicin 20 mg/kg and 
carbamylated darbepoetin at a dose of 50 mg /kg. The 
fifth group - doxorubicin 20 mg/kg was administered 
against doxorubicin 20 mg/kg, ethoxydol 50 mg/kg and 
carbamylated darbepoetin 50 mkg/kg were injected 
against its background. After 48 hours, the hearts were 
removed from animals under combined anesthesia (Xyla 
premedication 0.5 ml/kg, basic anesthesia - Zoletil (30 
mg/kg)), the aorta was cannulated and immediately 
connected to a heart-insulated Langendorf perfusion 
unit produced by Cardioprotect LLC, St. Petersburg 
(Russia). 
In the perfusion column was a standard Krebs-
Henseleite solution of the following composition (mmol): 
NaCl - 118.5; KCl - 4.7; MgSO4/7H2O - 1.2; KH2PO4 - 
1.2; CaCl2 - 1.5; glucose - 11.1; NaHCO3 –25.0. During 
the whole experiment, the pH and temperature of the 
solution were monitored by a pH-meter pH-410 and 
were 7.4±0.2 at 37 ° C. The oxygenation of the Krebs-
Henseleite solution was carried out with carbogen (95% 
O2, 5% CO2). The pressure of the perfusate at the exit of 
the aortic cannula was 85±5 mm. Hg, the perfusate 
delivery rate exceeded the speed of passage through 
the system of coronary arteries by 3-5 times. 
The contractile function of the heart was recorded 
using the “PhysExp Black Box” software and hardware 
complex manufactured by Cardioprotect LLC, St. 
Petersburg (the left ventricular diastolic pressure was 2–
7 mm Hg), with which all rats conducted the registration 
of indicators of contractility: maximum intraventricular 
pressure (IVP) (mm Hg), minimum IVP (mm Hg), 
average IVP (mm Hg), pulse IVP (mm Hg), heart rate 
(HR, beats/min), the maximum rate of contraction of the 
myocardium (+dP/dtmax, mm Hg/sec), the maximum rate 
of myocardial relaxation (-dP/dtmax, mmHg/sec). 
To determine the integral index reflecting the 
performance of calcium pumps of cardiomyocytes as a 
functional reserve of the heart, a hypercalcium solution 
was used under conditions of increasing frequency to 
480 bpm. The calcium concentration in this solution was 
5 mmol/l. 
To create a high frequency (480 beats/min), 
electrical stimulator connectors were successively 
connected, the catecholamine mediators were washed, 
the heart was perfused for 20 minutes with a solution 
with a normal calcium content, then a hypercalcium 
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solution (5 mmol/L) for 5 minutes). After perfusion, the 
heart was stimulated with electrical pulses using the 
STM 200-1 instrument from BiopacSystems, Inc. 
(California, USA) for 15 seconds. 
To assess the reserve capacity of the myocardium, 
we used the Tension-Time Index (tTTI) test of the 
“voltage over time” index calculated by the area under 
the curve of graphic recording of the minimum 
intraventricular pressure using the Origin pro 9.1 
program. As an isoline, the value of the minimum IVP 
preceding stimulation was set. 
Statistical data processing was carried out using the 
non-parametric Mann-Whitney test. The arithmetic 
mean and standard error of the mean were calculated. 
RESULTS 
After a single dose of doxorubicin in a dose of 20 
mg/kg, changes in the initial parameters of myocardial 
contractility were noted after 20 minutes of stabilization 
with perfusion with a standard Krebs-Henselyayt 
solution, namely, a significant decrease in UR, + dp/dt 
and –dp/dt, which suggests cardiotoxic doxorubicin at a 
dose of 20 mg/kg (Fig. 2 and 3). 
When using ethoxydol (E) on the model of 
doxorubicin cardiomyopathy, myocardial contractility 
indexes increase, the heart rate increases as compared 
with the negative control group, which indicates the 
cardioprotective effect of this substance. Also, when 
using carbamylated darbepoetin (CDEPO), against the 
background of doxorubicin cardiomyopathy, there is a 
positive trend in myocardial contractility indicators, but to 
a lesser extent than with ethoxydol. When using a 
combination of CDEPO and E, a significant 
improvement in myocardial contractility parameters is 
observed, their values approaching the level of the 
positive control group, which indicates a significant 
cardioprotective effect (Fig. 2 and 3). 
At the next stage of the study, the effect of ethoxydol, 
carbamylated darbepoetin, and their combination under 
hypercalcium (5 mmol/l) solution with high-frequency 
cardiac stimulation was evaluated, since doxorubicin 
cardiomyopathy is based on myocardial calcium 
overload. At this stage, a “defect of diastole” is also 
defined. 
When perfusing hearts in the Langendorff apparatus 
with a hypercalcium solution (5 mmol/l), a regular 
increase in the contractility parameter was found both in 
the group of intact animals and in groups with the 
simulation of doxorubicin cardiomyopathy. 
There is also a pattern in the greater cardioprotective 
effect when using ethoxydol as compared to CDEPO. 
The most pronounced effect is observed when using a 
combination of these substances (Fig. 2 and 3). 
 
Fig. 1. Load test with submaximal electrostimulation of a Langendorff-isolated rat heart. A - positive control group (0.9% 
NaCl); B - negative control group (doxorubicin 20 mg/kg); C - the main group (doxorubicin 20 mg/kg + ethoxydol 50 mg/kg) 
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Fig. 2. Effect of ethoxydol, carbamylated darbepoetin and their combination on the parameters of myocardial contractility 
(HR and HR) of the rat hearts isolated according to Langendorf when simulating doxorubicin cardiomyopathy under 
conditions of perfusion with norm and hypercalcium solutions. (M±m; n=10) 
Note: HR - heart rate (beats/min); IVP - intraventricular pressure (mm Hg.); * - p <0.05 relative to the group where doxorubicin was 
administered 
 
 
Fig. 3. Effect of ethoxydol, carbamylated darbepoetin, and their combination on the parameters of myocardial contractility 
(+ dt/dt, -dt/dt) isolated Langendorf hearts of rats when simulating doxorubicin cardiomyopathy under conditions of 
perfusion with normal and hypercalcium solutions. (M±m; n=10) 
Note: + dp/dt; -dp/dt - the maximum rate of reduction/relaxation of the myocardium (mm Hg./s). * - p <0.05 relative to the group where 
doxorubicin was administered 
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According to the test results with high-frequency 
electrostimulation and determination of Tension-Time 
Index (tTTI) by area along the curve of the minimum 
blood pressure in the simulation of doxorubicin 
cardiomyopathy, the area under the HR curve increased 
by 4 times, while using a combination of doxorubicin and 
CDEPO, the area is reduced by 41 % compared with the 
doxorubicin group (Fig. 4). 
CONCLUSION 
With the introduction of doxorubicin in a dose of 20 
mg/kg, a significant decrease in the parameters of 
myocardial contractility, an increase in heart rate, is 
observed intragastrically. The severity of changes in 
indicators was 63.5% compared with the positive control 
group. When used as a cardioprotector of ethoxydol at a 
dose of 50 mg/kg, a decrease in the toxic effect of DR 
and an improvement in performance by 14.8% 
compared with the group of DR. The degree of change 
in contractility indicators compared with the positive 
control group was 48.7%. As a result of CDEPO at a 
dose of 50 mg/kg, there is also a positive trend in the 
change in myocardial contractility, but to a lesser extent 
than in ethoxydol. The difference in performance 
compared with the DR group is 8.6%. The greatest 
cardioprotective effect was achieved by the introduction 
of a combination of DR and CDEPO. The increase in 
contractility compared with the doxorubicin group was 
23.9%. The severity of changes in contractility indicators 
decreased to 38.5% compared with the positive control 
group. This trend in the dynamics of myocardial 
contractility indices can be traced both in the conditions 
of perfusion with norcalcium and hypercalcium solutions. 
When determining the area under the curve of the 
minimum HRV with the introduction of doxorubicin, its 
increase by 4 times is observed, which indicates the 
development of a “diastole defect”. The most 
pronounced decrease in the area under the curve 
induced the introduction of a combination of doxorubicin 
and CDEPO. 
Since the greatest cardioprotective effect was 
revealed when using carbimylated darbepoetin and 
ethoxydol, we can speak of an additive type of 
interaction between these drugs. 
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